VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LEGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LEGNLegend Biotech Corporation
$16.25$3.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLEGNBalance Sheet

Legend Biotech Corporation (LEGN) Balance Sheet

9Y historyFree accessUpdated daily

Total debt declined from $389.3M in 2026Q1 to $167.4M in 2026Q3 and the debt-to-equity ratio fell to 0.13, though a current ratio of 3.95 and $460.7M in cash contrast with an accumulated deficit of roughly -$1.9B.

Income StatementBalance SheetCash FlowRatios

LEGN Balance Sheet

Annual statement

LEGN Balance Sheet

Legend Biotech Corporation (LEGN) balance sheet — 9-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17
Total Current Assets1.14B1.25B1.28B1.5B1.1B949.85M593.94M207.1M326.96M230.9M
Cash & Short-Term Investments852.5M948.6M1.12B1.31B1.03B882.39M506.07M159.18M216.18M2.12M
Cash Only460.7M901.9M286.75M1.28B786.03M688.94M456.07M83.62M210.17M2.12M
Short-Term Investments391.8M46.7M835.93M31M239.62M193.46M50M75.56M6.01M0
Accounts Receivable218.9M250.3M124.89M157.06M44.52M58.55M82.62M35.76M108.57M228.74M
Days Sales Outstanding57.3588.7972.67201.05138.87310.49402.06211.19806.533.54K
Inventory39.8M32M23.9M19.43M10.35M1.75M1.8M1.16M1.14M11K
Days Inventory Outstanding23.4928.6237.1949.1857.82-----41.82
Other Current Assets10.1M1.6M70K357K1.27M1.44M00255K760K
Total Non-Current Assets536.6M486.6M386.24M350.81M231.84M169.62M128.15M80.61M102.09M7.79M
Property, Plant & Equipment439.5M402M201.59M189.68M161.67M142.96M112.11M80.09M33.13M2.93M
Fixed Asset Turnover3.12x2.56x3.11x1.50x0.72x0.48x0.67x0.77x1.48x8.06x
Goodwill0000000000
Intangible Assets71.3M74.6M174.22M4.06M68.69M16.8M2.85M519K49K2K
Long-Term Investments5M5M4.36M4.36M04.71M00-1.24M-4.86M
Other Non-Current Assets25.8M5M6.06M152.42M1.49M5.15M13.19M01.24M4.86M
Total Assets1.68B1.73B1.67B1.85B1.33B1.12B722.09M287.71M429.05M238.69M
Asset Turnover0.80x0.59x0.38x0.15x0.09x0.06x0.10x0.21x0.11x0.10x
Asset Growth %4.41%3.8%-9.65%38.89%18.89%55.03%150.98%-32.94%79.75%-
Total Current Liabilities289.6M636.4M277.64M216.42M297.79M229.2M115.57M127.76M159.19M52.12M
Accounts Payable72M81.2M37.19M20.16M31.69M7.04M4.91M9.59M7.32M4.33M
Days Payables Outstanding47.672.6257.8751.02176.98-----16.48K
Short-Term Debt44.1M319.1M00001.79M1.03M00
Deferred Revenue (Current)18M11.3M47.41M53.01M451K304K55.01M46.29M40.32M30.21M
Other Current Liabilities1.1M1M500K68K67M87.9M31.45M64.22M34.16M38.08M
Current Ratio3.95x1.96x4.62x6.92x3.69x4.14x5.14x1.62x2.05x4.43x
Quick Ratio3.82x1.91x4.54x6.83x3.66x4.14x5.12x1.61x2.05x4.43x
Cash Conversion Cycle33.2444.7951.99199.2119.7----19.98K
Total Non-Current Liabilities119.1M95.2M351.96M380.82M288.86M124.32M6.7M282.82M261.21M174.4M
Long-Term Debt00301.2M281.33M260.93M120.46M0000
Capital Lease Obligations420.81M87.2M44.61M44.17M20.04M1.59M1.91M5.08M3.94M205K
Deferred Tax Liabilities0000004.24M0-213.2M-174.2M
Other Non-Current Liabilities7.6M8M-54K56K233K396K-274.52M000
Total Liabilities408.7M731.6M629.61M597.24M586.65M353.52M122.27M410.58M420.4M226.53M
Total Debt167.4M413.7M350.6M328.67M284.53M122.97M3.7M6.11M4.32M269K
Net Debt-293.3M-488.2M63.85M-949.04M-501.5M-565.97M-452.37M-77.51M-205.85M-1.85M
Debt / Equity0.13x0.41x0.34x0.26x0.38x0.16x0.01x-0.50x0.02x
Debt / EBITDA1.98x-------28.97x0.02x
Net Debt / EBITDA-3.48x--------1381.54x-0.13x
Interest Coverage3.27x-12.21x-6.32x-22.87x-40.29x-451.44x-73.20x-594.23x-18.71x-
Total Equity1.27B1B1.04B1.25B744.31M765.94M597.77M-122.87M8.65M12.17M
Equity Growth %35.99%-3.69%-16.85%68.12%-2.82%28.13%586.51%-1520.61%-28.91%-
Book Value per Share6.575.445.697.114.685.445.06-0.930.090.09
Total Shareholders' Equity1.27B1B1.04B1.25B744.31M765.94M597.77M-122.87M8.65M12.17M
Common Stock100K100K37K36K33K31K27K20K20K20K
Retained Earnings-1.93B-1.96B-1.66B-1.48B-966.46M-520.11M-116.53M-127.28M5.69M8.47M
Treasury Stock0000000000
Accumulated OCI122.6M122.2M-68.16M98.92M14.67M4.86M5.96M485K8.63M-236K
Minority Interest0000000000

Key Metrics

Growth RegimeExpanding
ProfitabilityWeak
Balance SheetAdequate
Cash FlowDeteriorating
Top Statement Risk

Persistent cash burn despite revenue

Balance Sheet Rebuilding Through Cash Accumulation

Based on reported quarterly figures, LEGN's cash balance rose from $201.3M in 2024Q2 to $460.7M in 2026Q3, while equity moved from roughly $1.2B to $1.3B, suggesting the balance sheet has strengthened in liquidity terms over the period.

The increase in cash appears to reflect a combination of collaboration receipts and capital raising rather than organic free cash flow, given that operating cash flow remained negative across most observed quarters. Total liabilities have also declined from $639.2M to $408.7M, which may indicate deleveraging or the settlement of deferred obligations. Investors should monitor whether the cash build is sustained once milestone-driven inflows normalize.

Leverage Falling as Debt Retires

As reported in financial statements, LEGN's total debt declined from $389.3M in 2026Q1 to $167.4M in 2026Q3, lowering the debt-to-equity ratio from 0.40 to 0.13 and reducing refinancing exposure.

The reduction in D/E to 0.13 appears to be a deliberate deleveraging rather than a forced restructuring, though the reported figures do not disclose the repayment source or terms. Lower leverage improves flexibility, but the persistence of negative operating cash flow means the company still depends on external funding or partner receipts for its obligations. The debt trajectory warrants continued monitoring alongside cash burn.

Strong Coverage but Burn-Dependent Runway

Based on reported figures, LEGN's current ratio stood at 3.95 in 2026Q3, down from 5.20 in 2025Q1, with $460.7M in cash providing a substantial buffer against near-term operating shocks.

A current ratio near 4 indicates ample short-term coverage, though the decline from above 5 suggests current liabilities have grown relative to current assets over the last several quarters. The true runway depends on quarterly operating cash burn, which the reported data indicates has been persistently negative. Liquidity appears adequate today, but its durability hinges on whether operating losses narrow.

Accumulated Deficit Dwarfs Equity Base

According to reported balance sheets, LEGN carries retained earnings of approximately -$1.9B against equity of about $1.3B, indicating that paid-in capital has funded a very large cumulative loss history.

The gap between accumulated deficit and equity signals that the company has relied heavily on external capital to finance its development and commercial build-out. Equity quality is therefore driven by new capital contributions rather than retained profitability. Stock-based compensation also contributes to equity dilution over time, which investors should weigh against the reported improvement in net income.

Reported Net Income Masks Weak Cash Quality

As reported in financial statements, LEGN posted $51.7M of net income in 2026Q3 while operating cash flow was negative at -$35.9M, a divergence that may make headline earnings misleading.

The gap between net income and operating cash flow suggests that working capital movements and non-cash items, including stock-based compensation, are carrying a large share of reported results. Balance sheet strength partly reflects capital raised and milestone timing rather than self-funded operations. Analysts should treat the improved balance sheet as dependent on continued partner and capital market access until cash generation becomes consistent.

LEGN — Frequently Asked Questions

Quick answers to the most common questions about buying LEGN stock.

What are the total assets of Legend Biotech Corporation (LEGN)?

As of 2025, Legend Biotech Corporation (LEGN) had total assets of $1.73B including $1.25B in current assets.

How much debt does Legend Biotech Corporation (LEGN) have?

Legend Biotech Corporation (LEGN) carries total debt of $413.7M, offset by $948.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Legend Biotech Corporation?

Legend Biotech Corporation (LEGN) has total shareholders' equity (book value) of $1.00B ($5.44 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Legend Biotech Corporation's current ratio and liquidity?

Legend Biotech Corporation (LEGN) reported a current ratio of 1.96x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.